Shenzhen Qianhai Health Innovation Zone
深圳前海健康创新区
The Shenzhen Qianhai Health Innovation Zone represents a breakthrough in cross-border medical cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Under the "Hong Kong and Macao Medicine and Device Measure," designating institutions in Qianhai can use drugs and medical devices that are already approved in Hong Kong or Macao but not yet registered in mainland China. This "Medical High Ground" focuses on integrating international standards of medical management with mainland China's world-class facilities, epitomized by the Shenzhen Qianhai Taikang International Hospital and its partnership with Cedars-Sinai.
Special Pilot Policies
GBA Drug and Device Measure (Early access)
Professional qualification recognition for HK/Macao staff
15% Individual Income Tax for international talent
Cross-border medical insurance settlement pilot
Hong Kong-style medical audit and management standards
Regulatory Advantage
Access to Hong Kong-approved drugs and devices before mainland approval.
Hub Institutions
Innovation & Research
Translational Medicine Hub
This zone acts as a bridge between laboratory research and clinical practice. Innovation focus areas include cell therapy, genomic sequencing, and robotic surgical training centers.
Travel & Logistics
Visa & Entry
Dedicated medical visa support is available for international patients seeking treatment in this zone. Streamlined travel for Hong Kong medical professionals and regional patients.
Patient Logistics
Hub institutions coordinate with luxury accommodation providers and airport recovery services to ensure a seamless medical journey.